Sakar Healthcare Limited (SAKAR) — Financial Results Announcement

StockFin.ai Try Free →

📢 Key Event
Sakar Healthcare reported Q4 FY26 results with oncology exports driving growth and reaffirmed FY27 targets.

🔄 What Changed
Revenue grew 42% YoY to ₹7,109.70 lakhs; PAT rose 91% YoY to ₹1,102.43 lakhs; oncology exports increased to INR30 lakhs from INR22 lakhs YoY; oncology's revenue share rose to 38% from 21% in FY25.

🔮 What's Next
FY27 revenue target of ~40% growth (INR380 crores); oncology exports expected to reach INR50-100 crores over two years; capacity utilization to rise to 50-55% in two years; gross margins to improve with oncology expansion.

💡 Investor Takeaway
Oncology exports are now a key growth driver, contributing 38% of revenue and expected to generate INR50-100 crores in exports over two years, supporting a 40% FY27 revenue growth target.

Sakar Healthcare reported Q4 FY26 revenue of **₹7,109.70 lakhs**, up 42% YoY, with EBITDA at **₹2,623.57 lakhs** (+67% YoY) and PAT at **₹1,102.43 lakhs** (+91% YoY). Oncology exports contributed **38% of total revenue**, reaching **INR30 lakhs** in Q4 (up from INR22 lakhs YoY), while domestic oncology revenue stood at **INR31 crores**. Management reaffirmed FY27 revenue growth of ~40% (INR380 crores) and projected oncology exports to generate **INR50-100 crores** over two years, targeting INR500 crores total revenue with oncology contributing 60%.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAKAR ✨ Ask AI About This

About Sakar Healthcare Limited (SAKAR)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,550.15 Cr P/E: 102.3

View full SAKAR stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Sakar Healthcare Limited (SAKAR) — Financial Results Announcement

About Sakar Healthcare Limited (SAKAR)

Recent Announcements from Sakar Healthcare Limited